# Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

> **NCT00089284** · PHASE1,PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 30 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma (NHL)

## Interventions

- **DRUG:** Rituxan
- **DRUG:** motexafin gadolinium
- **DRUG:** 111Indium-Zevalin and 90Yttrium-Zevalin

## Key facts

- **NCT ID:** NCT00089284
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-10-28
- **Primary completion:** 2007-01
- **Final completion:** 2008-08-20
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Due to lack of funding, phase II of study was not completed.
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089284, "Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00089284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*